MiNK Completes $40 Million IPO
MiNK Therapeutics, Inc. (“MiNK”) (NASDAQ-GM: INKT) recently completed an initial public offering of 3,333,334 shares of its common stock at a public offering price of $12.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $40 million.
Baird served as co-manager on this offering.
AboutMiNK is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. MiNK Therapeutics, Inc. is headquartered in New York, New York.
CONTACT US TO LEARN MORE
- October 2021
- MiNK Therapeutics, Inc.
- Equity Capital Markets
Biotechnology & Pharmaceuticals
- Target Location
- North America
BGRS, a subsidiary of Relo, combination with SIRVA, a portfolio company of MDP
BHI, a portfolio company of AEI, acquisition by Westinghouse, a portfolio company of Brookfield